IEEPA Tariff Refunds on Medical Devices and Supplies

Medical device and supply importers paid IEEPA surcharges on everything from surgical instruments to diagnostic equipment to personal protective equipment during the tariff period. The healthcare sector’s heavy reliance on imported components — particularly from China and other Asian manufacturing hubs — meant the IEEPA burden fell disproportionately on an industry already managing post-pandemic supply chain restructuring.

The Supreme Court’s February 2026 ruling in Learning Resources, Inc. v. Trump invalidated IEEPA tariffs. The CIT’s March 4 order directed CBP to process refunds. For medical device companies, hospital supply chains, and healthcare distributors, the recovery opportunity spans a wide range of products and can be substantial.

This guide covers what healthcare importers need to know about IEEPA recovery, including FDA-related considerations and industry-specific challenges. For the full recovery process, see the complete guide to IEEPA tariff refunds.

Which medical products qualify for IEEPA recovery

Any medical device, supply, or component imported from a covered country during the IEEPA period is eligible for IEEPA surcharge recovery. Major categories include:

Medical devices (Class I-III)

Diagnostic equipment. Imaging systems (CT, MRI components, ultrasound), patient monitors, laboratory analyzers, and point-of-care testing devices. These are high-value imports with significant per-entry IEEPA exposure.

Surgical instruments. Hand instruments, powered surgical tools, endoscopes, and laparoscopic instruments. China is a major manufacturer of stainless steel surgical instruments.

Implantable devices. Orthopedic implants, cardiovascular devices, dental implants, and their component materials. Many components are sourced from covered countries even when final assembly occurs domestically.

Disposable medical devices. Syringes, needles, catheters, tubing sets, and single-use surgical devices. These are high-volume, lower-value items where the cumulative IEEPA burden is significant.

Medical supplies

Personal protective equipment (PPE). Surgical masks, N95 respirators, gloves, gowns, and face shields. The massive PPE import surge during and after the pandemic created significant IEEPA exposure for healthcare systems and distributors.

Wound care products. Bandages, dressings, adhesive strips, and advanced wound care materials.

Sterilization supplies. Sterilization wraps, indicators, and packaging materials.

Laboratory supplies. Pipettes, tubes, slides, reagent containers, and lab consumables.

Pharmaceutical-adjacent products

Drug delivery devices. Inhalers, auto-injectors, infusion pumps, and drug-coated devices.

Packaging for pharmaceuticals. Vials, syringes (pre-filled), blister packs, and tamper-evident packaging imported from covered countries. See also our packaging materials guide.

Active pharmaceutical ingredients (APIs). While primarily classified as pharmaceutical products rather than devices, APIs imported from covered countries were subject to IEEPA surcharges and are recoverable. China is the world’s largest API producer.

Healthcare-specific recovery considerations

FDA registration and supply chain traceability

Medical device imports require FDA registration, 510(k) clearance or PMA approval, and supply chain documentation. The IEEPA recovery process is entirely separate from FDA compliance — filing for a tariff refund doesn’t affect your device’s regulatory status, and FDA data isn’t used in the customs recovery process.

However, the documentation required for FDA compliance can actually help your IEEPA recovery. FDA-required supply chain records, including:

• Device master records with component sourcing information
• Supplier qualification files
• Bill of materials with country-of-origin data

These records can supplement your customs entry data when building the master recovery dataset. Your quality/regulatory team may have documentation that your trade compliance team can use.

GPO and IDN contract implications

If you sell medical devices through Group Purchasing Organizations (GPOs) or to Integrated Delivery Networks (IDNs), your contract pricing may have been adjusted during the IEEPA period to reflect the tariff burden. The recovery creates potential downstream considerations:

Cost-plus contracts. If your GPO or IDN contract prices are calculated as cost-plus, and the cost basis included IEEPA duties, the recovery reduces your cost basis. The customer may be entitled to a retroactive price adjustment. Review your contractual obligations.

Fixed-price contracts with tariff escalation clauses. Some healthcare supply contracts include provisions for tariff-related price adjustments. The elimination of IEEPA tariffs may trigger a de-escalation.

Rebate structures. If your IEEPA-period pricing included rebates or discounts tied to tariff mitigation, the recovery may affect rebate calculations.

Hospital system importers

Large hospital systems that import directly (rather than through distributors) may have their own IEEPA claims. If your hospital is the importer of record, the recovery right belongs to the hospital, not to the device manufacturer. Check the IOR designation on your entry summaries.

Get your free Impact Assessment →

Calculating recovery for medical importers

Large medical device company

Annual import value from covered countries: $40 million

• Diagnostic equipment from Japan: $15M at 24% IEEPA = $3,600,000
• Components from China: $20M at 145% IEEPA = $29,000,000
• Supplies from Vietnam: $5M at 46% IEEPA = $2,300,000
• Total IEEPA recovery potential: $34,900,000
• Plus statutory interest: ~$2,000,000-$4,000,000

Medical supply distributor

Annual import value (PPE and disposables): $25 million from China

• IEEPA surcharge at 145%: $36,250,000
• The IEEPA surcharge alone was 145% of the product value

Hospital system (direct importer)

Annual import value: $5 million in surgical instruments and supplies from China

• IEEPA surcharge at 145%: $7,250,000
• Even a single hospital system’s imports can generate significant recovery

The statutory interest component adds 2-4% annually on these amounts from the date of payment to the date of refund. Over a typical 24-month processing period, interest on a $30 million claim would be approximately $1.2-$2.4 million. See the interest calculation methodology.

The PPE import dimension

The COVID-19 pandemic drove an unprecedented surge in PPE imports, much of it from China. Many healthcare organizations, government agencies, and distributors imported massive quantities of masks, gloves, gowns, and face shields during 2020-2024. When IEEPA surcharges were imposed in February 2025, PPE imports that continued faced the additional tariff burden.

Key considerations for PPE importers:

• PPE import volumes during the IEEPA period may have been declining from pandemic peaks but were still elevated compared to pre-pandemic levels
• Many PPE importers were first-time importers or infrequent importers who may not have robust customs documentation practices
• The documents required for IEEPA recovery include entry summaries and commercial invoices — ensure these are retained even if your PPE importing activity has since ended
• Some PPE imports may have received tariff exclusions during the pandemic period — verify whether those exclusions extended into the IEEPA period

Recovery paths for medical importers

The four recovery paths apply to medical products:

PSCs for unliquidated entries. Medical device companies with ongoing import programs likely have recent entries that haven’t liquidated yet. These are the fastest to recover — file immediately through your customs broker.

Protests for liquidated entries in the 180-day window. Medical importers with continuous monthly shipments will have entries at various stages. Build a deadline calendar and don’t miss the window.

CIT litigation for entries past the window. For large device companies with millions in IEEPA exposure, CIT action on entries outside the protest window is economically justified.

Immediate capital through claim assignment. Healthcare companies with capital-intensive R&D programs, clinical trials, or manufacturing expansions may benefit from converting IEEPA claims to immediate cash rather than waiting 18-36 months for government processing. See the treasury modeling guide for the NPV comparison.

Unique classification issues in medical

Medical products can have classification complexity that affects IEEPA recovery:

HTS classification challenges

Medical devices sometimes qualify for duty-free treatment under specific HTS provisions. If a product was correctly classified duty-free for MFN purposes but still assessed an IEEPA surcharge (because the surcharge applied based on country of origin, not product classification), the recovery is straightforward.

However, if a medical product was misclassified — for example, classified as a general-use product rather than a medical device, resulting in a different duty rate — the classification error may need to be corrected alongside the IEEPA recovery. Your compliance team should review classifications.

Pharmaceutical exclusions

Certain pharmaceutical products may have been excluded from IEEPA surcharges under executive order provisions. If your imports fall in the pharmaceutical space, verify whether the IEEPA surcharge was actually assessed before filing for recovery. The ES-003 report shows the actual duty amounts by HTS line.

Combination products

Products that combine a drug and a device (drug-eluting stents, pre-filled syringes, etc.) may have classification questions that affect both the MFN duty rate and the IEEPA surcharge assessment. Review these entries individually.

Supply chain resilience considerations

The pandemic exposed the vulnerability of healthcare supply chains dependent on Chinese manufacturing. IEEPA tariffs added financial pressure on top of supply chain disruption. With IEEPA tariffs eliminated and refunded:

Short-term: Recover the IEEPA duties paid during the tariff period. This is pure financial recovery with no operational changes required.

Medium-term: Reassess sourcing decisions made specifically to avoid IEEPA tariffs. If you shifted surgical instrument sourcing from China to Pakistan to avoid the 145% rate, the recovery changes the retroactive economics of that decision — though quality and supply security considerations remain.

Long-term: Continue building supply chain resilience through multi-sourcing and strategic inventory. The IEEPA experience reinforced what the pandemic already demonstrated: single-source dependence on any country creates unacceptable risk for healthcare supply chains.

The clinical laboratory perspective

Clinical and reference laboratories import significant volumes of reagents, consumables, instruments, and components from covered countries. Their IEEPA recovery considerations include:

Reagent and consumable imports. Laboratories consume high volumes of single-use items — test tubes, pipette tips, assay kits, culture media, and diagnostic reagents. Many of these are sourced from China and were subject to IEEPA surcharges. The per-item cost is low, but the cumulative volume makes the total IEEPA exposure significant.

Instrument components. Analytical instruments (mass spectrometers, chromatography systems, flow cytometers) often include components manufactured in covered countries. If the instrument was imported as a complete unit, the IEEPA surcharge was assessed on the full instrument value. If components were imported separately, each component entry has its own claim.

Reference materials and standards. Certified reference materials and calibration standards imported from covered countries were subject to IEEPA surcharges. These are essential for laboratory operations and are often sole-sourced from specific manufacturers.

Pharmaceutical manufacturer considerations

Pharmaceutical companies that import APIs (active pharmaceutical ingredients), excipients, and intermediates from China and India face substantial IEEPA recovery opportunities:

API imports from China. China supplies approximately 80% of the global API market. Pharmaceutical manufacturers importing APIs during the IEEPA period paid surcharges on materials that directly feed into drug production. The recovery on these imports can be enormous.

Excipient and inactive ingredient imports. Beyond APIs, pharmaceutical manufacturing requires imported excipients (binders, fillers, coatings, colorants) that were subject to IEEPA surcharges.

cGMP documentation. Pharmaceutical imports require current Good Manufacturing Practice (cGMP) documentation, including certificates of analysis, drug master files, and manufacturing records. These records complement the customs documentation needed for IEEPA recovery and can help verify product identity and origin.

Drug pricing implications. If the IEEPA surcharge was factored into drug pricing during the tariff period, the recovery may raise questions from government payers (Medicare, Medicaid) or pharmacy benefit managers about pricing adjustments. Pharmaceutical companies should proactively assess this exposure.

Telehealth and remote monitoring equipment

The growth of telehealth and remote patient monitoring during and after the pandemic drove increased imports of monitoring devices, sensors, and communication equipment from covered countries. These imports were subject to IEEPA surcharges:

Remote monitoring devices. Blood pressure monitors, pulse oximeters, glucose monitors, and wearable health devices imported from China and other covered countries.

Telehealth kits. Bundled equipment packages shipped to patients for remote consultation, including cameras, peripherals, and medical-grade peripherals.

Connected health infrastructure. Routers, gateways, and IoT devices used in hospital and clinical settings for connected health applications.

These products may be classified under medical device HTS codes or under general electronics codes depending on their FDA classification status. The IEEPA recovery applies regardless of which classification was used — verify that the surcharge was assessed and file accordingly.

Action plan for medical importers

1. Identify all IEEPA-period entries. Pull the ES-003 report and filter for entries with IEEPA surcharges.

2. Separate IEEPA from other duties. Medical products may carry MFN, Section 301, and IEEPA duties. Only IEEPA is recoverable.

3. Review GPO/IDN contracts. Flag any contracts with tariff adjustment or cost-plus provisions.

4. Coordinate with quality/regulatory. Leverage FDA documentation for supply chain traceability.

5. File on deadline-sensitive entries immediately. Don’t lose claims to the 180-day protest window.

6. Request an Impact Assessment. It provides the entry-level analysis that drives every downstream action.

The dental products dimension

The dental industry imports significant volumes of equipment and supplies from covered countries:

Dental instruments and handpieces. From basic hand instruments to advanced air-driven and electric handpieces, many dental tools are manufactured in China, Japan, and Germany.

Dental implant components. Implant fixtures, abutments, and prosthetic components. South Korea and China are growing sources for dental implant products.

Dental materials. Impression materials, cements, composites, and ceramics. Dental porcelain and zirconia blanks from China are particularly high-volume categories.

Digital dentistry equipment. Intraoral scanners, CAD/CAM milling machines, and 3D printers for dental applications. These high-value imports carry substantial per-entry IEEPA surcharges.

Dental practices and dental supply distributors who import directly should evaluate their IEEPA recovery opportunity. Even a single dental practice importing equipment directly from a covered country during the IEEPA period may have a claim worth pursuing.

Veterans Affairs and government healthcare

VA hospitals and military medical facilities that import medical equipment and supplies may have IEEPA recovery rights. Federal procurement rules add a layer of complexity:

Buy American Act. Some medical procurements are subject to the Buy American Act, which may have limited the volume of imported medical products. But exceptions exist, and covered imports occurred.

Federal Acquisition Regulation (FAR). Government contracts with medical suppliers may include cost-reimbursement provisions that affect how the IEEPA recovery is handled. If the government bore the tariff cost through contract pricing, the recovery may need to flow back to the government.

Trade Agreements Act (TAA) compliance. Some government medical procurements are restricted to TAA-designated countries. Products from TAA-compliant covered countries were still subject to IEEPA surcharges and are recoverable.

Healthcare companies can’t afford to leave IEEPA recovery capital on the table — not when it can fund patient care, R&D, or supply chain investment.

Request your free Impact Assessment to quantify your medical device and supply recovery →